Endocrine therapy in epithelial ovarian cancer (abstract +prior blog post) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, December 15, 2016

Endocrine therapy in epithelial ovarian cancer (abstract +prior blog post)



abstract

INTRODUCTION:
The estrogen receptor (ER) is expressed at high levels in many epithelial ovarian cancers (EOC) and represents a potential target for endocrine therapy. Both anti-estrogens and aromatase inhibitors have been evaluated in phase II clinical trials.
Areas covered: We present an overview of the phase II and phase III trials of anti-estrogens (tamoxifen and fulvestrant) and aromatase inhibitors (letrozole, anastrazole and exemestane) undertaken in epithelial ovarian cancer identified through a Pubmed search. We describe predictive biomarkers that are being investigated to identify responsive cancers.

Expert commentary:
The efficacy of endocrine therapy in epithelial ovarian cancer is likely to be confined to histological subtypes with the highest ER expression while low grade serous ovarian cancer appears to be one subgroup with good sensitivity to these agents. The low toxicity profile of these agents is favourable although their use is unlicensed and the optimal setting undefined. Prospective clinical trials of endocrine agents in the early relapse and maintenance settings are urgently required to establish their definitive role in the management of epithelial ovarian cancer.
                      ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
 

Sunday, June 12, 2016 (blog post date)

Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library



Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library
 

Ovarian Cancer

Gynecologic Cancer

2016 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.

2016 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. Jonathan A. Ledermann 5501
Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. David Marc Gershenson 5502
Multicenter phase II study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

0 comments :

Post a Comment

Your comments?